OncoSec Medical Inc


Stock Update (NASDAQ:ONCS): OncoSec Medical Inc Enrolls First Patient in Biomarker-Focused Pilot Study in Triple Negative Breast Cancer

OncoSec Medical Inc (NASDAQ:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that the Company has enrolled the first patient into a pilot …

Company Update (NASDAQ:ONCS): OncoSec Medical Inc Announces Fourth Quarter and YTD Results for Fiscal Year End 2015

OncoSec Medical Inc (NASDAQ:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced financial results for the fourth quarter and fiscal year ended July …

Maxim Weighs In On OncoSec Medical Inc Following Positive Clinical Trial Results In MCC

Maxim’s healthcare analyst Jason Kolbert weighed in today with an optimistic view on OncoSec Medical Inc (NASDAQ:ONCS), after the company announced positive results from a …

Company Update (NASDAQ:ONCS): OncoSec Medical Inc Appoints David P. Meininger as Senior Vice President of Business Development

OncoSec Medical Inc (NASDAQ:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced the appointment of David P. Meininger, PhD, MBA, to the newly created …

Company Update (NASDAQ:ONCS): OncoSec Medical Inc Promotes Sheela Mohan-Peterson to Chief Legal and Compliance Officer

OncoSec Medical Inc (NASDAQ:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, promoted Sheela Mohan-Peterson, JD, MS, to Chief Legal and Compliance Officer, effective August …

Maxim Maintains Buy On OncoSec Medical Inc Following First Patient Dosed In Phase II Clinical Trial For Unresectable Metastatic Melanoma

In a research report released Tuesday, Maxim analyst Jason Kolbert maintained a Buy rating on shares of OncoSec Medical Inc (NASDAQ:ONCS) with a $17.00 …

Stock Update (NASDAQ:ONCS): OncoSec Medical Inc Announces First Patient Enrolled in Phase II Clinical Trial Evaluating Combination of ImmunoPulse™ IL-12 and Anti-PD-1 Treatment

OncoSec Medical Inc (NASDAQ:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced enrollment of the first patient into the Phase II Investigator Sponsored …

OncoSec Medical Inc (ONCS): Upcoming Catalysts And Big Pharma Interest Has It Poised To Run

Those that follow my biotech recommendations know that I look for undervalued small cap stocks with significant upside. Some may be momentum plays, …

Company Update (NASDAQ:ONCS): OncoSec Medical Inc to Participate in Webcast on Advances in Cancer Immunotherapy

OncoSec Medical Inc (NASDAQ:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that Robert H. Pierce, MD, Chief Scientific Officer, will participate …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts